Reference
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Internet Document : 28 Nov 2023. Available from: URL: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous
Rights and permissions
About this article
Cite this article
Risk of T-cell malignancies after CAR T cell immunotherapy. Reactions Weekly 1986, 6 (2023). https://doi.org/10.1007/s40278-023-51311-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-51311-8